Literature DB >> 33043604

Long non-coding RNA ELDR enhances oral cancer growth by promoting ILF3-cyclin E1 signaling.

Subhayan Sur1, Hiroshi Nakanishi1, Robert Steele1, Dapeng Zhang2, Mark A Varvares3,4, Ratna B Ray1,3.   

Abstract

Oral squamous cell carcinoma (OSCC) is the sixth most common cancer with a 5-year overall survival rate of 50%. Thus, there is a critical need to understand the disease process, and to identify improved therapeutic strategies. Previously, we found the long non-coding RNA (lncRNA) EGFR long non-coding downstream RNA (ELDR) induced in a mouse tongue cancer model; however, its functional role in human oral cancer remained unknown. Here, we show that ELDR is highly expressed in OSCC patient samples and in cell lines. Overexpression of ELDR in normal non-tumorigenic oral keratinocytes induces cell proliferation, colony formation, and PCNA expression. We also show that ELDR depletion reduces OSCC cell proliferation and PCNA expression. Proteomics data identifies the RNA binding protein ILF3 as an interacting partner of ELDR. We further show that the ELDR-ILF3 axis regulates Cyclin E1 expression and phosphorylation of the retinoblastoma (RB) protein. Intratumoral injection of ELDR-specific siRNA reduces OSCC and PDX tumor growth in mice. These findings provide molecular insight into the role of ELDR in oral cancer and demonstrate that targeting ELDR has promising therapeutic potential.
© 2020 The Authors.

Entities:  

Keywords:  zzm321990EGFRzzm321990; Cyclin E1; EGFR long non-coding downstream RNA; ILF3; oral squamous cell carcinoma

Mesh:

Substances:

Year:  2020        PMID: 33043604      PMCID: PMC7726807          DOI: 10.15252/embr.202051042

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   9.071


  46 in total

1.  Identification of a novel AU-Rich element in the 3' untranslated region of epidermal growth factor receptor mRNA that is the target for regulated RNA-binding proteins.

Authors:  L A Balmer; D J Beveridge; J A Jazayeri; A M Thomson; C E Walker; P J Leedman
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  Cyclin E-induced S phase without activation of the pRb/E2F pathway.

Authors:  J Lukas; T Herzinger; K Hansen; M C Moroni; D Resnitzky; K Helin; S I Reed; J Bartek
Journal:  Genes Dev       Date:  1997-06-01       Impact factor: 11.361

3.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints.

Authors:  Bing Ren; Hieu Cam; Yasuhiko Takahashi; Thomas Volkert; Jolyon Terragni; Richard A Young; Brian David Dynlacht
Journal:  Genes Dev       Date:  2002-01-15       Impact factor: 11.361

4.  RB-dependent S-phase response to DNA damage.

Authors:  K E Knudsen; D Booth; S Naderi; Z Sever-Chroneos; A F Fribourg; I C Hunton; J R Feramisco; J Y Wang; E S Knudsen
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  Cyclin E1-CDK 2, a potential anticancer target.

Authors:  Dongdong Fang; Shuang Huang; Shi-Bing Su
Journal:  Aging (Albany NY)       Date:  2016-04       Impact factor: 5.682

Review 6.  Metabolomics of Head and Neck Cancer: A Mini-Review.

Authors:  Jae M Shin; Pachiyappan Kamarajan; J Christopher Fenno; Alexander H Rickard; Yvonne L Kapila
Journal:  Front Physiol       Date:  2016-11-08       Impact factor: 4.566

7.  Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1α co-activator driving oral cancer progression.

Authors:  Jing-Wen Shih; Wei-Fan Chiang; Alexander T H Wu; Ming-Heng Wu; Ling-Yu Wang; Yen-Ling Yu; Yu-Wen Hung; Wen-Chang Wang; Cheng-Ying Chu; Chiu-Lien Hung; Chun A Changou; Yun Yen; Hsing-Jien Kung
Journal:  Nat Commun       Date:  2017-06-22       Impact factor: 14.919

8.  Overexpression of CDK2 is a prognostic indicator of oral cancer progression.

Authors:  M Mihara; S Shintani; Y Nakahara; A Kiyota; Y Ueyama; T Matsumura; D T Wong
Journal:  Jpn J Cancer Res       Date:  2001-03

Review 9.  Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and clinical implications.

Authors:  Lei Zhang; Xiang Meng; Xin-Wei Zhu; Deng-Cheng Yang; Ran Chen; Yong Jiang; Tao Xu
Journal:  Mol Cancer       Date:  2019-05-27       Impact factor: 27.401

Review 10.  NF90 in posttranscriptional gene regulation and microRNA biogenesis.

Authors:  Kiyoshi Masuda; Yuki Kuwano; Kensei Nishida; Kazuhito Rokutan; Issei Imoto
Journal:  Int J Mol Sci       Date:  2013-08-19       Impact factor: 5.923

View more
  9 in total

Review 1.  Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance of Head and Neck Cancer: From Basic Research to Clinical Application.

Authors:  Xixia Zhang; Jing Yang
Journal:  Front Cell Dev Biol       Date:  2021-02-11

2.  Effects of long noncoding RNA on prognosis of oral squamous cell carcinoma: A protocol for systematic review and meta analysis.

Authors:  Qingjie Lin; Yong Zhang; Yanguo Liu; Xin Xu
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

3.  Analysis of the expression profile of serum exosomal lncRNA in breast cancer patients.

Authors:  Xin Zhao; Xuhui Guo; Dechuang Jiao; Jiujun Zhu; Hui Xiao; Yue Yang; Shengnan Zhao; Jingyang Zhang; Feifei Jiao; Zhenzhen Liu
Journal:  Ann Transl Med       Date:  2021-09

4.  Long noncoding RNA ELDR promotes cell cycle progression in normal oral keratinocytes through induction of a CTCF-FOXM1-AURKA signaling axis.

Authors:  Subhayan Sur; Robert Steele; Ben C B Ko; Jinsong Zhang; Ratna B Ray
Journal:  J Biol Chem       Date:  2022-04-01       Impact factor: 5.486

Review 5.  The role of lncRNAs and XIST in oral cancer.

Authors:  Huimin Liu; Dongxu Wang; Shaoning Kan; Ming Hao; Lu Chang; Pengxu Lu; Yangyang Liu; Ye Jin; Weiwei Liu
Journal:  Front Cell Dev Biol       Date:  2022-08-10

6.  ILF3 Is a Negative Transcriptional Regulator of Innate Immune Responses and Myeloid Dendritic Cell Maturation.

Authors:  Rodolfo Nazitto; Lynn M Amon; Fred D Mast; John D Aitchison; Alan Aderem; Jarrod S Johnson; Alan H Diercks
Journal:  J Immunol       Date:  2021-05-24       Impact factor: 5.426

7.  Long non-coding RNA ELDR enhances oral cancer growth by promoting ILF3-cyclin E1 signaling.

Authors:  Subhayan Sur; Hiroshi Nakanishi; Robert Steele; Dapeng Zhang; Mark A Varvares; Ratna B Ray
Journal:  EMBO Rep       Date:  2020-10-12       Impact factor: 9.071

8.  Momordicine-I, a Bitter Melon Bioactive Metabolite, Displays Anti-Tumor Activity in Head and Neck Cancer Involving c-Met and Downstream Signaling.

Authors:  Subhayan Sur; Robert Steele; T Scott Isbell; Kalyan Nagulapalli Venkata; Mostafa E Rateb; Ratna B Ray
Journal:  Cancers (Basel)       Date:  2021-03-21       Impact factor: 6.639

9.  LINC01783 accelerated tongue squamous cell carcinoma progression via inhibiting miR-199b-5p.

Authors:  Ying Hu; Xiaofeng Wang; Chong Li; Liang Jiao; Yi Du
Journal:  J Cell Mol Med       Date:  2021-08-07       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.